|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Malignant Mesothelioma | |||||
| Metastatic Cancer | |||||
| Peritoneal Cavity Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Mesothelioma | |||||
| Neoplasm Metastasis | |||||
| 3 | More general conditions related to this trial | ||||
| Adenoma | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Neoplasms, Mesothelial | |||||
| Neoplastic Processes | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| EF5 | |||||
| fluorescent antibody technique | |||||
| 5 | Sponsors listed in this trial | ||||
| University of Pennsylvania | |||||
| National Cancer Institute (NCI) | |||||